- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Novo Nordisk preps filings for sickle cell drug etavopivat | ||
| Di | MSD, Eisai report setback in first-line kidney cancer trial | ||
| Di | Jazz Pharma and Lilly cancer drugs cleared for use by NHS | ||
| Di | FDA kicks off review of Roche's Gazyva for wider lupus use | ||
| Di | Italy leads the way on child genetic disease diagnosis | ||
| Mo | Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia | ||
| Mo | UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator | ||
| Mo | Lilly said to be readying $2bn-plus bid for Kelonia | ||
| Mo | AZ is three for three with COPD hope tozorakimab | ||
| Mo | UCB cuts $1.15bn deal to buy epilepsy biotech Neurona | ||
| Fr | Obesity biotech Kailera's record-breaking IPO | ||
| Fr | OpenAI introduces GPT-Rosalind, its drug discovery AI | ||
| Fr | Multiple myeloma drug Blenrep backed for wider NHS use | ||
| Fr | Trump names Erica Schwartz to fill leadership void at CDC | ||
| Do | UK says it has hit target on commercial trial set-up times | ||
| Do | Lift for UK healthtech as fund bags £100m from national bank | ||
| Do | FDA accelerated approval path needs improvement, says ICER | ||
| Do | Lilly says Foundayo safety confirmed in ACHIEVE-4 trial | ||
| Do | Beeline raises $300m for BMS drugs, and other biofinancings | ||
| Do | Most patients "won't see benefit" with Alzheimer's drugs | ||
| 15.04. | Novartis CEO joins board of "responsible" AI firm Anthropic | ||
| 15.04. | Scientists issue call to arms over antifungal resistance | ||
| 15.04. | Daiichi exits OTC, with $1.55bn unit sale to Suntory | ||
| 15.04. | Parkinson's charity partners Biognosys on biomarker project | ||
| 15.04. | Amazon launches its AI drug discovery platform |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.